Related Experiment Videos
[Helicobacter pylori associated gastrointestinal mucosal lesions: is there an increased risk during therapy with
G Pöllmann1, W Kullich, G Klein
1Rehabilitationszentrum für rheumatische, Erkrankungen und Herzkreislauferkrankungen der PVAarb, Saalfelden, Osterreich.
Endpoints:
Are there connections between Helicobacter pylori-induced and NSAID-induced gastrointestinal mucosal lesions leading to an increased risk? Are there any diagnostic or therapeutic consequences?
Methods:
Evaluation of H.P. infection, NSAID medication and mucosal lesions in 303 patients with rheumatic diseases.
Results:
The prevalence of H.P. infection was 67.7%. Positive H.P. antibodies were found in 96.2% of patients with mucosal lesions, confirmed by endoscopy. There was no statistically significant increase of mucosal lesions in patients with both H.P.-infection and NSAID therapy.
Conclusions:
The main cause for gastrointestinal mucosal lesions is H.P. infection (> 90%). A general mucoprotective therapy in patients with H.P. infection and NSAID therapy cannot be supported. It may be supposed that a part of mucosal lesions connected to NSAID-therapy in recent decades probably was the consequence of H.P. infections. Eradication of H.P. might be of higher importance in the future.